Cell Line Development Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Cell Line Development Market is segmented by Product (Reagents and Media, Equipment, Finished Cells, and Other Products), Source, Application, End User, and Geography

Market Snapshot

img
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 10.6 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The global cancer burden has been increasing, and thus, cancer therapies must be modified according to regional and national priorities. 

  • According to the World Cancer Research Fund, in 2018, there had been an estimated 18 million cancer cases around the world, of which 9.5 million cases were in men and 8.5 million in women. 
  • Lung and breast cancers are the most common prevalent cancers, which contributed to about 12.3% of the total number of new cases that were diagnosed in 2018. Colorectal cancer was the third-most common cancer, with a prevalence of 1.8 million new cases in 2018, according to the World Cancer Research Fund.  
  • The increasing cancer burden is due to many related factors, including population growth and aging, and the changing prevalence of certain causes of cancer linked to social and economic developments. Cancer has also been associated with lifestyles.
  • The above-mentioned statistics indicate the high burden of cancer across the world, which is expected to drive the growth of cell line development market, as there is been an increasing demand for the novel therapeutics to deal with cancer.

Scope of the Report

As per the scope of this report, the cell line development market includes the types of equipment that have been used in the process along with the source from where the cell is extracted. Furthermore, the market studied includes different types of cell lines and the end users of the same.

By Product
Reagent and Media
Equipment
Finished Cells
Other Products
By Source
Mammalian Cell Line
Non-mammalian Cell Line
By Type of Cell Line
Recombinant Cell Lines
Hybridomas Technology
Vaccine Production
Drug Discovery
Other Applications
By End User
Biotech Companies
Academics and Research Institutes
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Mammalian Cell Line Development is Expected to Register Rapid Growth Over the Forecast Period

It has been observed that since the year 2006, there has been a rise in the number of recombinant protein therapeutics approved by the FDA. The National Institute of Health has stated that there were more than 15 novels recombinant protein therapeutics approved by the US Food and Drug Administration (FDA) each year. In addition, the expiration of the branded drugs has given rise to the emergence of biosimilars. As a result, there has been a growing demand for cell line development. Most of the biopharmaceutical companies that develop mammalian cell lines are based on either the methotrexate (MTX) amplification technology or the glutamine synthetase (GS) system.

With the utilization of mammalian cell lines, the cell clones obtained are highly heterogeneous and large numbers of cell clones have to be screened to identify rare stable high producer cell clones. To make the screening process easier, there have been several advances done in the mammalian cell line development, which has been making it the more preferred source for cell line development. Therefore, with the advancements being done in mammalian cell lines, the segment is expected to witness healthy growth during the future.

Cell Line Development - 1

United States Dominates the Market

The United States has a better healthcare infrastructure, compared to most of the developed countries. The presence of key players in the United States is the major factor propelling the growth of the market studied in the country. Furthermore, support from the US government to accelerate the research in the biotechnology and biopharmaceutical industry has been augmenting the demand for cell line development.

The Asia-Pacific is expected to witness the highest CAGR over the forecast period, due to the growing development in Asian countries, such as India, China, and Japan. Also, the Asia -Pacific market has been posing a great opportunity for new entrants to establish their market in this region.

Cell Line Development - 2

Competitive Landscape

The cell line development market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. The presence of major market players, such as Thermo Fisher Scientific, Sartorius AG, Promega Corporation, and Merck KGaA, has been, in turn, increasing the overall competitive rivalry in the market. Product advancements and improvement in the cell line development technology by the major players have been increasing the competitive rivalry.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Biopharmaceutical Industry

      2. 4.2.2 Rising Demand for Monoclonal Antibodies and Cancer Therapeutics

      3. 4.2.3 Growing Production of Biosimilars Due to the Patent Expiry of Branded Therapeutics

    3. 4.3 Market Restraints

      1. 4.3.1 Strict Regulations

      2. 4.3.2 Time Taking Process

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product

      1. 5.1.1 Reagent and Media

      2. 5.1.2 Equipment

      3. 5.1.3 Finished Cells

      4. 5.1.4 Other Products

    2. 5.2 By Source

      1. 5.2.1 Mammalian Cell Line

      2. 5.2.2 Non-mammalian Cell Line

    3. 5.3 By Type of Cell Line

      1. 5.3.1 Recombinant Cell Lines

      2. 5.3.2 Hybridomas Technology

      3. 5.3.3 Vaccine Production

      4. 5.3.4 Drug Discovery

      5. 5.3.5 Other Applications

    4. 5.4 By End User

      1. 5.4.1 Biotech Companies

      2. 5.4.2 Academics and Research Institutes

      3. 5.4.3 Other End Users

    5. 5.5 Geography

      1. 5.5.1 North America

        1. 5.5.1.1 United States

        2. 5.5.1.2 Canada

        3. 5.5.1.3 Mexico

      2. 5.5.2 Europe

        1. 5.5.2.1 Germany

        2. 5.5.2.2 United Kingdom

        3. 5.5.2.3 France

        4. 5.5.2.4 Italy

        5. 5.5.2.5 Spain

        6. 5.5.2.6 Rest of Europe

      3. 5.5.3 Asia-Pacific

        1. 5.5.3.1 China

        2. 5.5.3.2 Japan

        3. 5.5.3.3 India

        4. 5.5.3.4 Australia

        5. 5.5.3.5 South Korea

        6. 5.5.3.6 Rest of Asia-Pacific

      4. 5.5.4 Middle East & Africa

        1. 5.5.4.1 GCC

        2. 5.5.4.2 South Africa

        3. 5.5.4.3 Rest of Middle East & Africa

      5. 5.5.5 South America

        1. 5.5.5.1 Brazil

        2. 5.5.5.2 Argentina

        3. 5.5.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 American Type Culture Collection (ATCC)

      2. 6.1.2 Sartorius AG

      3. 6.1.3 Danaher Corporation

      4. 6.1.4 Merck KGaA

      5. 6.1.5 Thermo Fisher Scientific

      6. 6.1.6 WuXi Biologics

      7. 6.1.7 Corning Incorporated

      8. 6.1.8 Selexis SA

      9. 6.1.9 Promega Corporation

      10. 6.1.10 GE Healthcare

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Cell Line Development Market market is studied from 2018 - 2026.

The Cell Line Development Market is growing at a CAGR of 10.6% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Merck KGaA, Promega Corporation, Danaher Corporation, Sartorius AG, Thermo Fisher Scientific are the major companies operating in Cell Line Development Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!